홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
ALGS
#3365
Aligos Therapeutics, Inc. Common Stock
7.030
0
+1.30%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+1.30%
월간 변동
-19.10%
6달 변화
-28.19%
년간 변동율
-28.19%
이전 종가
6.940
0
Open
7.030
0
Bid
Ask
Low
7.030
0
High
7.030
0
양
2
마켓
주식
헬스케어
ALGS
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
1.53 M
1.58 M
1.59 M
2.9 M
6.11 M
—
Valuation ratios
Enterprise value
—
—
—
—
—
—
Price to earnings ratio
—
—
—
—
-1.9
-4.32
Price to sales ratio
—
—
—
—
46.99
87.35
Price to cash flow ratio
—
—
—
—
3.09
5.58
Price to book ratio
—
—
—
—
8.61
9.32
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.41
-0.55
-0.65
-0.58
-1.87
-1.5
Return on equity %
-0.49
-0.69
-0.92
-0.95
-4.53
-3.38
Return on invested capital %
-1 521.51
-1 526.49
-1 163.95
-1 725.24
-2 679.38
-3 114.08
Gross margin %
—
—
—
100
100
400
Operating margin %
—
—
—
-840.02
-1 678.67
-7 847.54
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
-835.75
-2 470.55
-11.14 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
8.26
5.25
4.03
5.9
2.86
21.43
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0.07
0.05
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
4 682.15
17.65 K
69.13 K
-30.73
-12.89
-9.49
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
-15.35 K
-31.4 K
-109.54 K
52.79
9.08
48.19
Net current asset value per share
-15.76 K
-31.19 K
-116.28 K
54.89
9.92
50.61
Tangible book value per share
-13.87 K
-28.19 K
-90.47 K
35.82
-4.62
26.97
Working capital per share
-13.85 K
-25.25 K
-87.44 K
45.59
6.45
40.55
Book value per share
-13.87 K
-28.19 K
-90.47 K
35.82
-4.62
26.97
뉴스
앨리고스 테라퓨틱스, H.C. Wainwright ’매수’ 등급 유지
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress
앨리고스 테라퓨틱스, 2상 HBV 연구 진전 소식에 주가 상승
Aligos Therapeutics stock rises on Phase 2 HBV study progress
앨리고스, B형 간염 치료제 2상 연구 진전 보고
Aligos reports progress on Phase 2 hepatitis B drug study
Aligos, James Hassard 최고 상업 책임자 임명
Aligos therapeutics appoints James Hassard as chief commercial officer
길리어드 대항마? Aligos, UBS ’매수’ 의견 제시
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline
알리고스, THR-β 작용제 병용 시너지 효과 발표
Aligos reports synergistic weight loss effect with THR-β agonist